Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Liabilities: 2020-2024

Historic Total Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $18.2 million.

  • SAB Biotherapeutics' Total Liabilities rose 8.76% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 8.76%. This contributed to the annual value of $18.2 million for FY2024, which is 31.59% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Total Liabilities of $18.2 million as of FY2024, which was down 31.59% from $26.6 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Total Liabilities registered a high of $42.6 million during FY2021, and its lowest value of $17.5 million during FY2020.
  • In the last 3 years, SAB Biotherapeutics' Total Liabilities had a median value of $19.8 million in 2022 and averaged $21.6 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Total Liabilities spiked by 142.96% in 2021 and then plummeted by 53.40% in 2022.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Total Liabilities stood at $17.5 million in 2020, then soared by 142.96% to $42.6 million in 2021, then crashed by 53.40% to $19.8 million in 2022, then spiked by 34.24% to $26.6 million in 2023, then slumped by 31.59% to $18.2 million in 2024.